. CEO James C. Katzaroff stated “We are very grateful for the continued support and commitment of the Cadwell family and associated entities. This important step, as the company moves to normalize its capital structure and balance sheet, is in anticipation of capitalizing the company to pursue commercial opportunities for our Y-90 product line.”
I think the FDA approval of Y-90 is now imminent...!.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.